An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
The Government of India has initiated an Offer for Sale (OFS) for the Life Insurance…
The Pacific island nation which previously used the name Nauru has officially made a shift…
Staying updated with current affairs is one of the most important aspects of competitive exam…
Annapurni Subramaniam, an Indian astrophysicist, has received the COSPAR Vikram Sarabhai Medal for the year…
Nathan Thomas, an engineering teacher in the America, has achieved the record of being the…
The Union and Staff Service Secretariate were initiated with various reforms to bring speed, transparency,…